M249 melanoma cells: Vemurafenib and Selumetinib resistant through BRAF double minutes vs. parental. M249 melanoma cells: Vemurafenib and Selumetinib resistant through BRAF double minutes vs. parental

CGH profiling of M249 melanoma cell line treated with step-wise increasing Vemurafenib and Selumetinib to develop resistance (VSR). The resistance mechanims was through BRAF amplification in double minute (DM) format. The control cell line is untreated M249. Overall design: Two-condition experiment, M249 Parental vs M249 VSR DM. Biological replicates: 1 control replicate, 1 treated replicate.